GLP-1R activation for the treatment of stroke: Updating and future perspectives

Reviews in Endocrine and Metabolic Disorders

Volumn 15, Issue 3, 2014, Pages 233-242

  Darsalia, Vladimer ^a   Nathanson, David ^a   Nyström, Thomas ^a   Klein, Thomas ^b   Sjöholm, Åke ^c,d   Patrone, Cesare ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

^d Sodertalje Hospital   (Sweden)

Author keywords

Alogliptin; Diabetes; DPP 4 inhibitors; Exenatide; Exendin; GLP 1; Incretin mimetics; Linagliptin; Liraglutide; Lixisenatide; Saxagliptin; Sitagliptin; Stroke; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR;

AGING; ANTIDIABETIC ACTIVITY; ATHEROSCLEROSIS; BRAIN DAMAGE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIABETIC PATIENT; DISABILITY; DRUG EFFICACY; DRUG SAFETY; ENTEROENDOCRINE CELL; GLUCAGON RELEASE; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RELEASE; LIFESTYLE; LIFESTYLE MODIFICATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RECEPTOR UPREGULATION; REVIEW; RISK FACTOR; RISK MANAGEMENT; SMOKING; AGONISTS; ANIMAL; METABOLISM; STROKE;

ANIMALS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; RECEPTORS, GLUCAGON; STROKE;

EID: 84906078482     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-014-9285-9     Document Type: Review

References (135)

1. Go AS et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245.
2. Taqi MA et al. Past, present, and future of endovascular stroke therapies. Neurology. 2012;79(13 Suppl 1):S213-20.
3. Diener HC et al. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment. Lancet Neurol. 2013;12(7):677-88.
4. Herlitz J et al. Early identification and delay to treatment in myocardial infarction and stroke: differences and similarities. Scand J Trauma Resusc Emerg Med. 2010;18:48.
5. Crimmins DS et al. Acute stroke and transient ischaemic attack management-time to act fast. Intern Med J. 2009;39(5):325-31.
6. Kurz MW, Kurz KD, Farbu E. Acute ischemic stroke-from symptom recognition to thrombolysis. Acta Neurol Scand Suppl. 2013;196:57-64.
7. Whiteley WN et al. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43(11):2904-9.
8. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007;24(1):1-10. (Pubitemid 47026135)
9. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med. 2011;17(11):1391-401.
10. Hossmann KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol. 1994;36(4):557-65.
11. Macdonald RL, Stoodley M. Pathophysiology of cerebral ischemia. Neurol Med Chir (Tokyo). 1998;38(1):1-11. (Pubitemid 28071102)
12. Ferrer I, Planas AM. Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. J Neuropathol Exp Neurol. 2003;62(4):329-39. (Pubitemid 36403033)
13. Liu R et al. Neuroprotection targeting ischemic penumbra and beyond for the treatment of ischemic stroke. Neurol Res. 2012;34(4):331-7.
14. Heiss WD. The ischemic penumbra: How does tissue injury evolve? Ann N Y Acad Sci. 2012;1268:26-34.
15. Sacco RL et al. Experimental treatments for acute ischaemic stroke. Lancet. 2007;369(9558):331-41. (Pubitemid 46136492)
16. O'Collins VE et al. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59(3):467-77. (Pubitemid 43358067)
17. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx. 2004;1(1):36-45. (Pubitemid 46589340)
18. Endres M et al. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis. 2008;25(3):268-78. (Pubitemid 351450431)
19. Gladstone DJ et al. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 2002;33(8):2123-36. (Pubitemid 34840080)
20. Sena E et al. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci. 2007;30(9):433-9. (Pubitemid 47374833)
21. Li Y et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A. 2009;106(4):1285-90.
22. Teramoto, S., et al., Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab, 2011.
23. Yang D et al. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res. 2013;1517:104-13.
24. Lee CH et al. Ischemia-Induced Changes in Glucagon-Like Peptide-1 Receptor and Neuroprotective Effect of Its Agonist, Exendin-4, in Experimental Transient Cerebral Ischemia. Journal of Neuroscience Research. 2011;89(7):1103-13.
25. Briyal S, Gulati K, Gulati A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res. 2012;1427:23-34.
26. Darsalia V et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond). 2012;122(10):473-83.
27. Darsalia V et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2013;62(4):1289-96.
28. Gupta, V., Pleiotropic effects of incretins. Indian J Endocrinol Metab, 2012. 16 (Suppl1): p. S47-56.
29. Ban K et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340-50. (Pubitemid 351653542)
30. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117(1):24-32. (Pubitemid 46048446)
31. Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21(2):91-117. (Pubitemid 40467658)
32. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. 2004;47:357-66. (Pubitemid 38491230)
33. Mannucci E et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med. 2000;17(10):713-9.
34. Vilsboll T et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609-13. (Pubitemid 32195226)
35. Lugari R et al. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res. 2002;34(3):150-4. (Pubitemid 34293273)
36. Jin T. Why diabetes patients are more prone to the development of colon cancer? Med Hypotheses. 2008;71(2):241-4.
37. Yi F et al. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology. 2008;149(5):2341-51. (Pubitemid 351574509)
38. Ahren B, Carr RD, Deacon CF. Incretin hormone secretion over the day. Vitam Horm. 2010;84:203-20.
39. Toft-Nielsen MB et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-23.
40. Nathanson D et al. Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease. Diabetologia. 2010;53(2):277-80.
41. Muscelli E et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57(5):1340-8.
42. Rask E et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care. 2001;24(9):1640-5. (Pubitemid 33716463)
43. Vilsboll T et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88(6):2706-13. (Pubitemid 36724446)
44. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-39. (Pubitemid 350041474)
45. Balks HJ et al. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab. 1997;82(3):786-90. (Pubitemid 27106588)
46. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A. 1992;89(18):8641-5.
47. Stoffel M et al. Human glucagon-like peptide-1 receptor gene. Localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6. Diabetes. 1993;42(8):1215-8. (Pubitemid 23219942)
48. Goke R et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650-5. (Pubitemid 23270754)
49. Thorens B et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes. 1993;42(11):1678-82. (Pubitemid 23318127)
50. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6):876-913. (Pubitemid 30647076)
51. Orskov C et al. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes. 1996;45(6):832-5. (Pubitemid 26168585)
52. Barragan JM et al. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol. 1999;277(5 Pt 1):E784-91.
53. Yamamoto H et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110(1):43-52. (Pubitemid 34743464)
54. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor-or not? Endocrinology. 2013;154(1):4-8.
55. Panjwani N et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE (-/-) mice. Endocrinology. 2013;154(1):127-39.
56. Fehmann HC et al. Ligand-specificity of the rat GLP-I receptor recombinantly expressed in Chinese hamster ovary (CHO-) cells. Z Gastroenterol. 1994;32(4):203-7.
57. Holz, G.G.t., W.M. Kuhtreiber, and J.F. Habener, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature, 1993;361:(6410): p. 362-5. (Pubitemid 23041630)
58. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch. 1998;435(5):583-94. (Pubitemid 28098639)
59. Lu M et al. The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I (7-37). Endocrinology. 1993;132(1):94-100. (Pubitemid 23019487)
60. Xu G et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270-6. (Pubitemid 30395416)
61. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-37.
62. Erdogdu O et al. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol. 2013;50(2):229-41.
63. Erdogdu O et al. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2010;325(1-2):26-35.
64. Parthsarathy V, Holscher C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS One. 2013;8(3):e58784.
65. Baraboi ED et al. Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. Am J Physiol Regul Integr Comp Physiol. 2011;301(4):R1011-24.
66. Knauf C et al. Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. Diabetes. 2008;57(10):2603-12.
67. Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs. 2012;26(10):871-82.
68. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909-17.
69. Raufman JP et al. Actions of Gilamonster venom on dispersed acini from guinea pig pancreas. Am J Physiol. 1982;242(5):G470-4. (Pubitemid 12099993)
70. Kolterman OG et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62(2):173-81. (Pubitemid 40674548)
71. AMYLIN PHARMACEUTICALS, I.B.e.i.p.i.A.P., Inc. San Diego (CA) USA . 2005.
72. Buse JB et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-35. (Pubitemid 39441462)
73. DeFronzo RA et al. Effects of exenatide (exendin-4) on glycemic control andweight over 30 weeks inmetformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092-100. (Pubitemid 40616618)
74. Kendall DM et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083-91. (Pubitemid 40616617)
75. Blevins T et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-10.
76. Diamant M et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-43.
77. Drucker DJ et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-50.
78. Byetta: exenatide injection [package insert]. San Diego, C., Amylin Pharmaceuticals, 2005. Available from http://pi.lilly.com/us/byettapi.pdf., Assessed 27 September 2010.
79. Moretto TJ et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448-60.
80. Best JH et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2011;34(1):90-5.
81. Agerso H et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45(2):195-202. (Pubitemid 34208381)
82. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705. (Pubitemid 46048557)
83. Buse JB et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
84. Garber A et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-81.
85. Russell-Jones D et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046-55.
86. Zinman B et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224-30.
87. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther. 2009;31(11):2472-88.
88. Victoza: liraglutide (rDNA origin) injection [package insert]. Princetown, N., Novo Nordisk, 2010. Available from http://www.victozapro.com/ pdf/Victoza-ComboPI-5.24.pdf. Assessed 27 September 2010, 2010.
89. Christensen M, Knop FK. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? Curr Diab Rep. 2010;10(2):124-32.
90. Werner U. Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010. Ann Endocrinol (Paris). 2008;69(2):164-5.
91. Jimenez-Solem E et al. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther. 2010;12(6):790-7.
92. St Onge, E.L. and S.A.Miller, Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opin Biol Ther, 2010;10:(5): p. 801-6.
93. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60(11):1454-70. (Pubitemid 44560347)
94. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 2007;30(6):1335-43. (Pubitemid 46871135)
95. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011;55(1-3):10-6.
96. Lambeir AM et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209-94.
97. Waget A et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology. 2011;152(8):3018-29.
98. Goke R et al. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995;7(11):2294-300.
99. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999;403(2):261-80. (Pubitemid 28566834)
100. Hamilton, A. and C. Holscher, Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport, 2009.
101. Bertilsson G et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res. 2008;86(2):326-38. (Pubitemid 351196738)
102. Iwai T et al. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res. 2006;55(4):352-60. (Pubitemid 43866249)
103. Chowen JA et al. Increased glucagon-like peptide-1 receptor expression in glia after mechanical lesion of the rat brain. Neuropeptides. 1999;33(3):212-5. (Pubitemid 29398142)
104. Holscher, C., Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol, 2013.
105. Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol. 2010;159(3):495-501.
106. Salcedo I et al. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. British Journal of Pharmacology. 2012;166(5):1586-99.
107. Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin. 2011;27(3):547-58.
108. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003;27(3):313-8.
109. Sato K et al. Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci. 2013;14(11):21513-24.
110. Daly SC et al. Exenatide in acute ischemic stroke. Int J Stroke. 2013;8(7):E44.
111. McIntyre RS et al. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res. 2013;237:164-71.
112. Luciani P et al. Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model. Cell Mol Life Sci. 2010;67(21):3711-23.
113. Perry T et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300(3):958-66. (Pubitemid 34165002)
114. Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci. 2009;10(12):861-72.
115. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187-215.
116. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res. 2012;9(2):109-16.
117. Abbott CA et al. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics. 1994;40(5):331-8. (Pubitemid 24299322)
118. Mentzel S et al. Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem. 1996;44(5):445-61. (Pubitemid 26131673)
119. Takasawa W et al. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun. 2010;401(1):7-12.
120. Kroller-Schon S et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res. 2012;96(1):140-9.
121. Rohnert P et al. Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflammation. 2012;9:44.
122. Pipatpiboon N et al. DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur J Neurosci. 2013;37(5):839-49.
123. Pintana, H., et al., DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin resistant rats. J Endocrinol, 2013.
124. Johansen OE et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a Phase 3 programme. Cardiovasc Diabetol. 2012;11(1):3.
125. Monami M et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27 Suppl 3:57-64.
126. Gallwitz B et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-83.
127. Scirica, B.M., et al., Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med, 2013.
128. White, W.B., et al., Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med, 2013.
129. Nauck MA et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 Pt 1):E981-8.
130. Tolessa T et al. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci. 1998;43(10):2284-90. (Pubitemid 28487260)
131. Wettergren A et al. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut. 1997;40(5):597-601. (Pubitemid 27278325)
132. Wishart JM et al. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides. 1998;19(6):1049-53. (Pubitemid 28383802)
133. Burcelin R. The gut-brain axis: a major glucoregulatory player. Diabetes Metab. 2010;36 Suppl 3:S54-8.
134. Plamboeck A et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol. 2013;304(12):G1117-27.
135. Cheyuo C et al. The parasympathetic nervous system in the quest for stroke therapeutics. J Cereb Blood Flow Metab. 2011;31(5):1187-95.